Jun 2026 (Q2 FY26) — Jul 30, 2026
Castle Biosciences Q2 FY26 — Strong Revenue Growth and Raised Full-Year Guidance
Read the full callCastle Biosciences (CSTL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Castle Biosciences earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 104 | +20.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -3.0 | +2.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -2.1 | −145.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$33.8 +2.08% · +$0.69
Performance +51.2% 1Y
1Y: $22.36 on 14 Oct 2025 → $33.8. High $43.04 (26 Jan 2026), low $18.15 (13 May 2026).
- Previous close
- $33.11
- 52-week range
- $18.15 – $43.04
- One year
- +50.16%
Overview
- Symbol
- CSTL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Castle Biosciences earnings calls (CSTL)
Financials
What the filings say
Net profit, year on year: −146% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 86 | 86 | 88 | 86 | 83 | 87 | 84 | 104 |
| Operating profit | 5 | 4 | -28 | -4 | -7 | -4 | -18 | -3 |
| Operating margin | 5.9% | 4.7% | −31.7% | −4.9% | −8.2% | −4.4% | −22.0% | −3.0% |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 2 | 10 | -26 | 5 | -1 | -2 | -15 | -2 |
| EPS ($ per share) | 0.08 | — | -0.90 | 0.16 | -0.02 | — | -0.49 | -0.07 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -57 | -52 | -62 | -94 | -161 | -218 | -200 | -224 |
| Total liabilities | 32 | 35 | 24 | 51 | 48 | 62 | 75 | 108 |
| Fixed assets | 2 | 2 | 7 | 10 | 14 | 25 | 51 | 97 |
| Investments | — | — | — | — | — | 144 | 173 | 183 |
| Total assets | 22 | 120 | 439 | 463 | 447 | 453 | 531 | 579 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12 | 7 | 10 | -19 | -42 | -6 | 65 | 64 |
| Cash from investing | -0 | -1 | -5 | -67 | -167 | -16 | -50 | -60 |
| Cash from financing | 16 | 88 | 306 | 5 | 2 | -2 | 6 | -7 |
| Net cash flow | 3 | 94 | 311 | -80 | -207 | -24 | 21 | -3 |
| Capital expenditure | -0 | -1 | -5 | -3 | -6 | -14 | -28 | -36 |
| Free cash flow | -13 | 6 | 5 | -22 | -47 | -19 | 37 | 28 |
Insider filings
284 filings between Oct 20, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$18.99M
214 sales by 5 insiders
96% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 4
- Award — granted as compensation
- 50
- Option exercise — converted options into shares
- 16
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| MAETZOLD DEREK J | — | $11.18M | Oct 5, 2026 |
| Oelschlager Kristen M | — | $3.34M | Oct 1, 2026 |
| Juvenal Tobin W | — | $2.81M | Oct 12, 2026 |
| Stokes Frank | — | $1.46M | Aug 14, 2026 |
| Cole G Bradley | — | $210.7K | Mar 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 3,288 | $110.6K |
| Oct 5, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 3,198 | $113.7K |
| Oct 5, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 8,580 | $305.2K |
| Oct 5, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Option exercise 10b5-1 plan | 8,165 | $19.5K |
| Oct 5, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 2,718 | $96.7K |
| Oct 1, 2026 | Oelschlager Kristen M Chief Operating Officer | Option exercise 10b5-1 plan | 4,153 | $14.0K |
| Oct 1, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale 10b5-1 plan | 2,807 | $100.4K |
| Oct 1, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale 10b5-1 plan | 1,346 | $49.0K |
| Sep 30, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 1,034 | $35.4K |
| Sep 29, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 5,543 | $196.8K |
| Sep 21, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 8,580 | $303.2K |
| Sep 21, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 3,198 | $113.0K |
| Sep 21, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 2,718 | $96.0K |
| Sep 21, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Option exercise 10b5-1 plan | 8,580 | $20.5K |
| Sep 15, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 3,294 | $115.8K |
| Sep 14, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 3,306 | $106.9K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Option exercise 10b5-1 plan | 8,584 | $20.5K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 8,361 | $267.6K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 3,124 | $100.0K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 71 | $2.3K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 2,656 | $85.0K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 223 | $7.3K |
| Sep 11, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 83 | $2.7K |
| Sep 1, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale 10b5-1 plan | 3,952 | $131.8K |
| Sep 1, 2026 | Oelschlager Kristen M Chief Operating Officer | Option exercise 10b5-1 plan | 4,152 | $14.0K |
| Sep 1, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale 10b5-1 plan | 200 | $6.8K |
| Aug 31, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 1,730 | $56.8K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 21 | $711 |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 21 | $711 |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 21 | $711 |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 257 | $8.5K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 257 | $8.5K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 257 | $8.5K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 11,472 | $380.2K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 2,505 | $83.0K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 2,129 | $70.6K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 177 | $6.0K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 257 | $8.5K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 956 | $32.4K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 209 | $7.1K |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 21 | $711 |
| Aug 28, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Option exercise 10b5-1 plan | 12,428 | $29.7K |
| Aug 25, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 9,050 | $317.1K |
| Aug 25, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale | 5,223 | $180.9K |
| Aug 25, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale | 7,161 | $245.4K |
| Aug 24, 2026 | Oelschlager Kristen M Chief Operating Officer | Sale | 12,218 | $411.6K |
| Aug 17, 2026 | Juvenal Tobin W Chief Commercial Officer | Sale 10b5-1 plan | 1,730 | $51.2K |
| Aug 14, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 1,100 | $33.0K |
| Aug 14, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Option exercise 10b5-1 plan | 1,100 | $2.6K |
| Aug 14, 2026 | MAETZOLD DEREK J Pres. & Chief Exec. Officer | Sale 10b5-1 plan | 2,714 | $81.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CASTLE BIOSCIENCES INC
Free account. Everything above stays public.
Write why you follow CASTLE BIOSCIENCES INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading